Bio‑Techne Corporation announced the launch and first shipment of its next‑generation Leo™ System on December 9, 2025. The new platform adds dual‑channel fluorescence detection to the company’s existing chemiluminescence capability, enabling researchers to quantify up to 24 targets per sample, assess proteoforms, and multiplex same‑weight targets in a single run. The system can process 100 capillaries in three hours and delivers a variability of only 5–6%, a performance that meets the stringent precision requirements of regulated laboratories.
The dual‑channel fluorescence feature expands the Leo™ System’s multiplexing options to four distinct modes, giving users the flexibility to choose the most appropriate detection chemistry for each assay. In addition, the platform is fully 21 CFR Part 11 compliant, allowing it to be used in clinical and pharmaceutical development workflows that demand electronic record‑keeping and audit trails. These capabilities position the Leo™ System as a high‑throughput solution for both academic research and regulated drug discovery projects.
Bio‑Techne’s Protein Sciences portfolio, which generated more than $1.2 billion in annual revenue, has shown flat organic growth in recent quarters—$1.2 billion in FY 2024 and a 1% organic increase in Q1 FY 2025—while the Diagnostics and Spatial Biology segment grew 14% organically. The new Leo™ System is therefore a strategic tool to reinvigorate the Protein Sciences segment, which has lagged behind its peers. By offering a more versatile and precise platform, Bio‑Techne aims to capture market share in the highly competitive protein analysis space and to drive incremental revenue in a segment that has been a growth bottleneck.
Will Geist, President of the Protein Sciences segment, said the next‑generation Leo™ System “sets a new standard for our customers by delivering unmatched precision and efficiency in protein analysis.” The company’s leadership views the launch as a key lever to accelerate adoption in regulated environments, where the combination of fluorescence and chemiluminescence can reduce assay development time and lower costs for end users.
The enhanced Leo™ System is expected to strengthen Bio‑Techne’s competitive position against rivals that offer single‑mode detection platforms. By providing a fourth multiplexing option, the company can appeal to laboratories that require both fluorescence and chemiluminescence in a single instrument, potentially increasing sales volume and customer stickiness. The launch also aligns with Bio‑Techne’s broader strategy to expand its Protein Sciences portfolio and to offset the modest growth seen in its core segment, thereby supporting long‑term revenue growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.